Temozolomide in resistant or relapsed pediatric solid tumors.
about
Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomasPhase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor studyTemozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single instituteDocetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.Initial testing (stage 1) of temozolomide by the pediatric preclinical testing programPretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cellsConnexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.The use of palliative chemotherapy in pediatric oncology patients: a national survey of pediatric oncologists.Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis.Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
P2860
Q24234049-9B892979-7011-4FCB-8245-AF3D91590616Q33409117-B1E614A5-A975-4470-93C5-16FA8F30B48EQ33413067-D3289DC0-3854-420B-8916-CF47E0D5DFC9Q33418020-FEDE5E8C-D8EE-47A9-8910-33967F8D25D7Q33439510-67E4574C-C851-44CD-BA92-6F5A5B9C11D2Q34344177-14F41DE4-C006-45C8-AEC6-93031C8BA710Q34571940-7666657E-12C4-4F63-BCF7-8570F35EF8E9Q35811082-C559580D-40FC-4B2D-86CF-352E72E1820EQ37419856-69F1FA7E-6B5E-4389-8A47-FCEC5C9F6ACAQ38891614-D9E6E404-BE98-4C86-A980-A33FAAE30238Q41003114-1FB2688E-2A24-46FD-83F3-3BA2E5084F9DQ44596535-ADC378A6-A1AF-4DDA-8CEC-6B42303C00A8Q44611540-8805E694-1157-416F-8035-9804A2A2B6AEQ45078921-6F861AFC-129D-48D8-809C-D0CF36181D99Q45193912-662AFEE0-3079-44E0-BCCE-42AC1A162B6EQ46469386-9BE59960-1878-4EB7-B34E-C766D37A3C83Q51021522-79687BF1-5555-497B-9DFA-1652C9BC1B0EQ52150588-CFD2CEDB-3D24-47B8-8D83-F685821C2DE8
P2860
Temozolomide in resistant or relapsed pediatric solid tumors.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Temozolomide in resistant or relapsed pediatric solid tumors.
@ast
Temozolomide in resistant or relapsed pediatric solid tumors.
@en
type
label
Temozolomide in resistant or relapsed pediatric solid tumors.
@ast
Temozolomide in resistant or relapsed pediatric solid tumors.
@en
prefLabel
Temozolomide in resistant or relapsed pediatric solid tumors.
@ast
Temozolomide in resistant or relapsed pediatric solid tumors.
@en
P2093
P2860
P356
P1476
Temozolomide in resistant or relapsed pediatric solid tumors.
@en
P2093
A Castellano
A Donfrancesco
C Dominici
G M Milano
P2860
P356
10.1002/PBC.20516
P577
2006-07-01T00:00:00Z